Stasia Obremskey

Stasia Obremskey is the Managing Director of RH Capital Funds an impact venture capital fund of Rhia Ventures where she is responsible for investing in innovations in women’s reproductive health.  She joined Rhia Ventures at its founding in 2018 after more than twenty-five years of experience as an interim CFO for non-profit organizations and start-up companies and an impact investor and philanthropist in women’s reproductive health.  She holds a bachelor’s degree in Business Administration with a concentration in Finance from the University of Notre Dame and an MBA from the Harvard Graduate School of Business. She has extensive experience as a member of several nonprofit boards where she has held a number of leadership positions.  Stasia is a founding member of The Maverick Collective, an initiative of PSI.  As the proud mother of three young adults, she is working with scientists and entrepreneurs to find the next generation of hormone-free contraceptives to meet their sexual health needs.

Valentina Milanova

Valentina Milanova is the founder of Daye, the gynae health research and development company on a mission to close the gender pain gap and overcome historical gender biases in medical research and product innovation. After years of research and testing, Daye launched its first consumer product in 2020 - the world‘s only cramp-soothing tampon.  From the outset, Valentina has baked her core values into the DNA of the company - Daye‘s products are created by women who used to be in the prison system, and their tampons are produced in a fully carbon neutral operation. Born and raised in Bulgaria, Valentina moved to the UK to attend the University of Buckingham, where she got degrees in business, economics, and law.  After considering careers in journalism and econometrics, Valentina soon found herself drawn in by the start-up world, working first at Techstars and then as a venture associate for Founders Factory. Meanwhile, she began working on her own idea for a company. After 180 pitches to investors, Valentina managed to raise £4.23 million in seed funding and in 2018, Daye started officially changing the face of female health for the better.

Marco Rüedi

Marco is Entrepreneur, Coach and Trainer in the Swiss Start-up ecosystem with 20+ years international experience in strategic and operational roles across the LifeScience Industry and Healthcare Management. He is also currently a mentor for the Tech4Eva program at EPFL Innovation Park.

He is a strong believer in well-balanced teams: motivated to challenge the status quo!
Passionate to work with the next generation of Entrepreneurs/Managers for the challenges of tomorrow. He focused on Start-up and Innovation Management, Translational medicine. His motto is “From idea to market”.

He holds a Medical Doctor from the University of Fribourg, Berne and Zurich, an Executive Masters in Medical Management from eMMM PHW Berne, and an Executive Masters in Business Administration from eMBA PHW Berne.

Kerry Briggs

Matthieu Vallin

Matthieu Vallin joined Octopus Ventures in 2020 and focuses on sourcing and qualifying early-stage investments that will transform healthcare and life sciences. From consumer health through to advances in drug discovery, he liaises with entrepreneurs who have a drive to bring the most benefits to the delivery of care and patient outcomes.

Eileen Buttimer

Eileen Buttimer is Senior Vice President of New Business Development at Sagentia Innovation and has over 20 years’ experience exploring innovation opportunities with clients across multiple sectors including consumer health, pharma and med tech.  She is particularly passionate about driving innovation in the Women’s Health space.  Eileen is a strong professional skilled in International Business, Innovation Management, Entrepreneurship and Market Analysis.  She holds a PhD in Biochemistry and an MBA and prior to Sagentia Innovation, she has held R&D management positions in DuPont and Pfizer.

Avi Gesser

Shannon Altimari

Shannon joined GSK in 2020 as the company’s Global Head of Oncology Advocacy to Outcomes. In this role, she leads GSK’s oncology patient advocacy strategies, with a focus on improving outcomes and supporting equitable access for patients. Prior to GSK, she was with TESARO Bio GmbH as Head of International Corporate Affairs. Before TESARO, she spent 10 years with Biogen. She is an American citizen currently living in Switzerland.

Shannon Altimari

Shannon joined GSK in 2020 as the company’s Global Head of Oncology Advocacy to Outcomes. In this role, she leads GSK’s oncology patient advocacy strategies, with a focus on improving outcomes and supporting equitable access for patients. Prior to GSK, she was with TESARO Bio GmbH as Head of International Corporate Affairs. Before TESARO, she spent 10 years with Biogen. She is an American citizen currently living in Switzerland.